Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC21 Treprostinil
D06213 Treprostinil (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Pulmonary Antihypertensives
Prostacyclin Vasodilators
Treprostinil
D06213 Treprostinil (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D06213 Treprostinil (JAN/USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG00161 Treprostinil
D06213 Treprostinil
Hormonal agent
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
DG00161 Treprostinil
D06213 Treprostinil
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00161 Treprostinil
D06213 Treprostinil
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostacyclin
PTGIR
D06213 Treprostinil (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06213
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06213
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06213
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06213
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG00161 Treprostinil
Hormonal agent
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
DG00161 Treprostinil
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00161 Treprostinil